%A Zhang,Jingcheng
%A Cao,Zhe
%A Yang,Gang
%A You,Lei
%A Zhang,Taiping
%A Zhao,Yupei
%D 2019
%J Frontiers in Oncology
%C
%F
%G English
%K microRNA,MicroRNA-27a,Signaling Pathways,biomarker,clinical application
%Q
%R 10.3389/fonc.2019.00893
%W
%L
%M
%P
%7
%8 2019-September-12
%9 Review
%#
%! MicroRNA-27a (miR-27a) in solid tumors: a review based on mechanisms and clinical observations
%*
%<
%T MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations
%U https://www.frontiersin.org/articles/10.3389/fonc.2019.00893
%V 9
%0 JOURNAL ARTICLE
%@ 2234-943X
%X MicroRNAs (miRNAs) are a family of highly conserved, non-coding single-stranded RNAs transcribed as ~70 nucleotide precursors to an 18–22 nucleotide product (1). miRNAs can silence their homologous target genes at the post-transcriptional level, and these genes have been revealed to play an important role in tumorigenesis, invasion and metastasis (2). MicroRNA-27a (miR-27a), transcripted by miR-27a gene, has proved to implicate with many kinds of solid tumors, showing potential as a useful biomarker or drug target for clinical application. However, even though miR-27a has been reported in many cancers, the mechanism and signal pathways of miR-27 in oncogenesis, invasion, and metastasis are still obscure. Moreover, recent studies show that miR-27a pays an important role in epithelial-mesenchymal-transition, regulating tumor immune response, and chemoresistance. In this review, we summarize the current literature, demonstrate the established link between miR-27a and tumorigenesis, and focus on recently identified mechanisms. The review also aims to demonstrate the potential of miR-27a as a diagnostic and/or prognostic biomarker in solid tumors and to discuss the possibilities of targeted therapy and drug design.